CSL Behring Commitment

For more than 100 years, CSL Behring has specialized in plasma therapies to improve the quality of life in patients with bleeding disorders, immune deficiencies, inherited emphysema, and other conditions.

CSL Behring offers many programs and services to the bleeding disorders community, in addition to its range of blood products. Some of these include:

Sponsoring programs and activities that benefit people with bleeding disorders
Working with government authorities to help make sure patients have access to care
Improving and expanding educational and outreach efforts
Funding medical research

Featured programs and services of the CSL Behring Commitment include:

CSL Behring Foundation for Research and Advancement of Patient Health

This is the only nonprofit foundation dedicated exclusively to charitable, scientific, and educational endeavors that benefit the bleeding disorders community. The Foundation provides grants for research projects and community initiatives that advance the standard of care for people with bleeding disorders. More>>

Gettin’ in the Game^SM

Gettin’ in the Game^SM was started by CSL Behring to encourage kids with bleeding disorders to be physically active. Children and their families can get sports tips from professional athletes, participate in exercises or sports competitions, and meet other kids with bleeding disorders. More>>

Gettin’ in the Game^SM Junior National Championship

The JNC is a fun-filled annual golf and baseball competition for children ages 7 through 18. More>>

Reimbursement Resource Center

Call 1-800-676-4266 for expert advice and information about insurance matters, including health insurance reimbursement for CSL Behring products. More>>

Patient Assistance Program

This program provides medically necessary therapies to qualified patients who are uninsured, underinsured, or who cannot afford their prescribed therapy. More>>

Project Red Flag (PRF)

Project Red Flag (PRF) is a campaign by the National Hemophilia Foundation aimed at educating women and their healthcare providers about the symptoms, diagnosis, and treatment of bleeding disorders. CSL Behring proudly supports PRF, along with the Centers for Disease Control and Prevention. More >>

VWD Consumer Advisory Committee

CSL Behring hosts meetings with VWD patients and parents to keep current on the needs and interests of the VWD community, and to provide a forum for consumers to exchange ideas.

For more information about any of the programs and services offered by CSL Behring, call our Consumer Affairs Center at 1-888-508-6978.

Important Safety Information

Stimate Nasal Spray is indicated for patients with hemophilia A with Factor VIII coagulant activity levels greater than 5%. Desmopressin acetate is not indicated for the treatment of hemophilia A with Factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have Factor VIII antibodies.

Stimate^® Nasal Spray is indicated for patients with mild to moderate classic type 1 von Willebrand disease (VWD) with Factor VIII levels greater than 5%. Stimate^® Nasal Spray is not indicated for the treatment of severe classic VWD (Type I) and when there is evidence of an abnormal molecular form of Factor VIII antigen.

Stimate^® Nasal Spray is contraindicated if you have a known hypersensitivity to desmopressin or any of the components of Stimate. Stimate should not be used by patients with type 2B VWD, since platelet aggregation may be induced. Stimate Nasal Spray is for intranasal use only.

To reduce the potential for water intoxication or hyponatremia, especially in the young and the elderly, patients using desmopressin may be advised to reduce fluid intake, ingesting only enough to satisfy thirst. Your doctor will monitor for a rare occurrence of an extreme decrease in plasma osmolality that could result in seizures, possibly leading to coma.

Other adverse reactions reported with use of injectable and/or intranasal desmopressin acetate include headache, nausea, somnolence (sleepiness), dizziness, chest pain, palpitations and tachycardia (rapid heartbeat), and severe allergic reactions, including anaphylaxis. See full prescribing information for a complete list of adverse reactions.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 .